Pharma BD Deal Intelligence
GSK paid $454M for a next-gen antibody platform in 2007 that, nearly two decades later, has not produced a single marketed medicine under its own name — the technology was absorbed into GSK's broader biopharm R&D (AlbudAb fusion format lives on in early-stage trials) but never delivered the transformative pipeline GSK paid for.
Full analysis, sources & comparables →Domantis CEO Bob Connelly said "Everybody has to be able to play in the antibody sector now," and that dAbs offered "a combination therapy in one product";…
GEN reported the £230M/$454M all-cash transaction and listed Domantis indications under development — rheumatoid arthritis, asthma, COPD and multiple myeloma —…
Pharmafile reported Domantis had previously raised $83 million in venture capital since its 2000 launch and that GSK's £230 million purchase placed it "at the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
GlaxoSmithKline acquired Domantis Limited, a Cambridge UK domain-antibody (dAb) developer, for GBP 230M (~$454M) in cash to extend its biologics platform. Remove the trailing 'Source:' clause.
GSK paid $454M for a next-gen antibody platform in 2007 that, nearly two decades later, has not produced a single marketed medicine under its own name — the technology was absorbed into GSK's broader biopharm R&D (AlbudAb fusion format lives on in early-stage trials) but never delivered the transformative pipeline GSK paid for.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Domantis Limited (this deal) | 2007 | $454M | 38 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2007 deals · GlaxoSmithKline plc deals